The ATM expansion signals continued cash burn and reliance on equity financing for a micro-cap pharma. Traders should expect near-term selling pressure as shares are placed into the market. Monitor for any pipeline catalysts or operational updates that could offset dilution concerns.
Price Chart
Executive Summary
Rocket One Inc. (RKTO) filed a 424B5 prospectus supplement to increase its at-the-market (ATM) offering by up to $2.66 million in common stock, bringing total potential gross proceeds under the existing Sales Agreement with H.C. Wainwright to approximately $9.3 million. The company has already sold 6.8 million shares for ~$6.6 million under this agreement, and the new tranche represents ~19% dilution relative to the current public float of ~20.5 million shares. This is a dilutive capital raise for a micro-cap pharmaceutical company with a $14M market cap, signaling ongoing cash needs.
Key Facts
- Rocket One is offering up to an additional $2,661,176 of common stock under an existing ATM Sales Agreement with H.C. Wainwright.
- Since November 2024, the company has already sold 6,824,327 shares for gross proceeds of ~$6.6 million under the same agreement.
- The offering is limited by General Instruction I.B.6 of Form S-3 to one-third of public float ($27.8M) in any 12-month period.
- As of May 27, 2026, the company had 21,022,498 shares outstanding, with a public float of 20,468,902 shares.
- The stock closed at $1.36 per share on May 27, 2026, giving the company a market cap of ~$14M.
- The filing is an amendment to a prior S-3 shelf registration (File No. 333-291566) and prospectus supplement dated April 16, 2026.
Financial Impact
Up to $2.66 million in additional gross proceeds from new share sales; potential dilution of ~19% relative to current public float if fully sold at $1.36/share.
Risk Factors
- Further dilution if the full $2.66M is sold, increasing share count by up to ~1.96 million shares at current price.
- Ongoing cash burn without clear revenue or near-term catalyst may lead to additional future offerings.
- Micro-cap pharma with $14M market cap is highly sensitive to equity issuance; stock could trade lower as ATM shares hit the market.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001213900-26-061613 |
| Document: 0001213900-26-061613-index-headers.html | 0001213900-26-061613 |
| Document: 0001213900-26-061613-index.html | 0001213900-26-061613 |
| Document: 0001213900-26-061613.txt | 0001213900-26-061613 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | DEF 14A | — | awaiting T+20 | — | — |
Jun 3, 2026 20w ago | 8-K | $2.14 $0.8880 | ▼ −58.50% | ▼ −57.50% | — |
Jun 3, 2026 20w ago | 8-K | $2.14 $0.8880 | ▲ +58.50% | ▲ +57.50% | — |
Jun 3, 2026 20w ago | 424B5 | $2.14 $0.8880 | ▲ +58.50% | ▲ +57.50% | — |
Jun 2, 2026 20w ago | 8-K | $2.14 $0.8880 | ▼ −58.50% | ▼ −57.50% | — |
May 28, 2026 21w ago | 8-K | $1.70 $0.9508 | ▼ −44.07% | ▼ −41.63% | — |
May 27, 2026 21w ago | 424B5 | $1.70 $0.9508 | ▲ +44.07% | ▲ +41.63% | — |
May 27, 2026 21w ago | 8-K | $1.36 $0.8750 | ▼ −35.66% | ▼ −33.76% | — |
May 4, 2026 24w ago | 8-K | $0.7100 $2.22 | ▼ −212.68% | ▼ −207.72% | — |
Apr 16, 2026 27w ago | 8-K | $0.7300 $0.6660 | ▼ −8.77% | ▼ −14.14% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers